Detail akcie Epigenomics Rg online

Business Summary: Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Epigenomics AG revenues increased from EUR0K to EUR4K. Net loss applicable to common stockholders decreased 74% to EUR204K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other Operating Expense - Balancing val decrease of 66% to EUR151K (expense).